Market Overview - The animal health sector increased by 1.25% on September 5, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - Yongshun Biological (839729) closed at 10.82, up 4.14% with a trading volume of 44,500 shares and a turnover of 47.80 million yuan [1] - Shilian Biological (688098) closed at 11.76, up 3.16% with a trading volume of 114,100 shares and a turnover of 132 million yuan [1] - Other notable performers include: - Houfeng Holdings (002141): closed at 3.96, up 2.33% [1] - KQ Biological (688526): closed at 18.00, up 2.16% [1] - Dayu Biological (871970): closed at 10.25, up 2.09% [1] Capital Flow - The animal health sector experienced a net outflow of 37.19 million yuan from institutional investors, while retail investors saw a net inflow of 13.24 million yuan [2] - Notable capital flows include: - Shilian Biological: net inflow of 500.11 thousand yuan from institutional investors [3] - Houfeng Holdings: net inflow of 91.15 thousand yuan from retail investors [3] - KQ Biological: net outflow of 297.54 thousand yuan from institutional investors [3]

Market Overview - The animal health sector experienced a decline of 0.2% on September 4, with Shunlian Biological leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the animal health sector included: - Qudongli (code: 838275) with a closing price of 11.96, up 6.50% [1] - Dayu Biological (code: 871970) with a closing price of 10.04, up 3.40% [1] - Yongshun Biological (code: 839729) with a closing price of 10.39, up 2.26% [1] - Conversely, Shunlian Biological (code: 688098) saw a decline of 2.98%, closing at 11.40 [2] Trading Volume and Capital Flow - The total trading volume for the animal health sector showed a net outflow of 85.41 million yuan from institutional investors, while retail investors saw a net inflow of 74.17 million yuan [2] - The capital flow for individual stocks indicated significant movements, with Shunlian Biological experiencing a net outflow of 10.12 million yuan from institutional investors [3] Individual Stock Analysis - Shunlian Biological had a total trading volume of 131,200 shares, with a net inflow of 7.73 million yuan from retail investors [3] - Other stocks like Huisheng Biological (code: 300871) and ST Green Kang (code: 002868) also showed varied capital flows, with Huisheng experiencing a net outflow of 12.50 million yuan from speculative funds [3]

Market Overview - On September 4, A-shares experienced a significant decline, with the Shanghai Composite Index dropping by 1.25%, the Shenzhen Component Index by 2.83%, the ChiNext Index by 4.25%, and the Sci-Tech 50 Index falling over 6% [1][9]. Market Performance - A total of 2,297 stocks rose, while 2,990 stocks fell, with 43 stocks hitting the daily limit up and 47 stocks hitting the daily limit down [1][3]. - The total trading volume reached 25,818.93 billion, with a total trading amount of 162,553.5 million [3]. Sector Analysis - Consumer stocks, including retail and food sectors, saw gains, with several stocks like Guoguang Chain and Anji Food hitting the daily limit up [3]. - In contrast, semiconductor and computing-related stocks faced substantial declines, with many stocks dropping over 10%, including Cambridge Technology and Zhongji Xuchuang [5][6][7]. Analyst Insights - Analysts attribute the market's sharp adjustment to the rapid previous gains, leading to profit-taking pressures, compounded by misleading rumors [9]. - Despite the downturn, analysts maintain a positive outlook on the Chinese market, citing sustainable upward momentum and supportive regulatory measures from the China Securities Regulatory Commission [9]. - Historical patterns suggest that such adjustments are common in bull markets, typically lasting 2-3 trading days, with expectations of new highs following the correction [9].

Market Overview - The animal health sector experienced a decline of 2.2% on September 3, with the leading stock, Driveline, falling by 8.33% [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] Stock Performance - Key stocks in the animal health sector showed significant declines, with Driveline (code: 838275) closing at 11.23, down 8.33% on a trading volume of 49,500 shares and a transaction value of 57.66 million yuan [1] - Other notable declines included: - Yongshun Biological (code: 839729) down 4.78% to 10.16 [1] - Jinhai Biological (code: 002688) down 4.03% to 6.91 [1] - ST Lvkang (code: 002868) down 3.30% to 26.35 [1] - Houbang Holdings (code: 002141) down 3.24% to 3.88 [1] Capital Flow - The animal health sector saw a net outflow of 108 million yuan from major funds, while retail investors contributed a net inflow of 101 million yuan [1] - Detailed capital flow for specific stocks indicated: - Shunlian Biological (code: 688098) had a net inflow of 8.21 million yuan from major funds [2] - ST Lvkang (code: 002868) experienced a net outflow of 2.26 million yuan from major funds [2] - Houbang Holdings (code: 002141) faced a significant net outflow of 24.59 million yuan from major funds [2]

Market Overview - The animal health sector increased by 1.34% on September 1, with Jinhe Biology leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Stock Performance - Jinhe Biology (002688) closed at 7.53, up 6.06% with a trading volume of 875,700 shares and a turnover of 651 million yuan [1] - Other notable performers included *ST Lvkang (002868) with a 5.02% increase, and Shunlian Biology (688098) with a 1.78% increase [1] - The overall trading data for the animal health sector is summarized in the provided table [1] Capital Flow - The animal health sector saw a net inflow of 26.58 million yuan from institutional investors, while retail investors experienced a net outflow of 7.06 million yuan [2] - The detailed capital flow for individual stocks indicates varying levels of institutional and retail participation [3] Individual Stock Analysis - Jinhe Biology had a net inflow of 88.59 million yuan from institutional investors, while retail investors showed a net outflow of 37.91 million yuan [3] - Other stocks like Kexin Biology (688526) and *ST Lvkang (002868) also experienced mixed capital flows, with significant retail outflows [3]

会议召开方式：上证路演中心网络互动 证券代码：688526 证券简称：科前生物 公告编号：2025-045 武汉科前生物股份有限公司 关于参加 2025 年半年度科创板生物制品及 CXO 行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 09 月 15 日 （星期一） 15:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 投资者可于 2025 年 09 月 08 日 （星期一） 至 09 月 12 日 （星 期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过公司邮箱 wuhankqbio@kqbio.com 进行提问。公司将在说明会 上对投资者普遍关注的问题进行回答。 武汉科前生物股份有限公司（以下简称"公司"）已于 2025 年 08 月 26 日发布公司 2025 年半年度报告，为便于广大投资者更全面 深入地了解公司 2025 年半年度经营成果、财务 ...

Investment Rating - The report maintains a "Strong Buy" investment rating for the company [1][7][3] Core Views - The profitability of the downstream breeding sector is gradually improving, leading to a continuous recovery in the company's performance for the first half of 2025. The company achieved a revenue of 487 million yuan, representing a year-on-year increase of 22%, and a net profit attributable to shareholders of 220 million yuan, up 44% year-on-year [7] - The improvement in demand and the rich product matrix have contributed to a sequential improvement in gross margin, which increased by 2.83 percentage points to 68.7% in Q2 2025. The company has also received four new veterinary drug registration certificates, including new vaccines for pigs, which are expected to contribute to profit growth [7] - The anti-involution policy may boost pig prices, which could enhance the demand for animal health products and improve the overall breeding sector's profitability, positively impacting the company's performance [7] Financial Data and Valuation - The company’s total revenue is projected to be 1,064 million yuan in 2023, with a year-on-year growth of 6%. However, a decline of 11% is expected in 2024, followed by a recovery with growth rates of 24%, 14%, and 11% in 2025, 2026, and 2027 respectively [2][13] - The net profit attributable to shareholders is forecasted to be 396 million yuan in 2023, with a slight decline of 3% in 2024, and then a recovery with growth rates of 16%, 14%, and 16% in the following years [2][13] - The company’s price-to-earnings (PE) ratio is expected to decrease from 21.6 in 2023 to 14.5 by 2027, indicating an improving valuation over time [2][14] Stock Performance - The company's stock has shown an absolute performance increase of 55% over the past 12 months, outperforming the benchmark index [5]

Group 1 - The report highlights the growth trend in the treatment of hemorrhoids products and the potential for expanding into wet wipes business, with a focus on the company's strong performance in the first half of 2025 [5][6][7] - The company achieved a revenue of 1.949 billion yuan in H1 2025, a year-on-year increase of 1.11%, and a net profit of 343 million yuan, up 10.04% year-on-year [6][7] - The company is extending its product line into the field of anal health, with rapid growth in wet wipes, leveraging its established brand recognition and user base [7] Group 2 - The report discusses the strategic focus on financial technology and the acceleration of AI model applications by the company, which reported a revenue of 1.208 billion yuan in H1 2025, a decrease of 48.55% year-on-year [8][9] - The company is narrowing its business focus to financial technology, reducing non-financial IT business, while maintaining investment in core technology and product areas [9][10] - The new generation of core products is being developed to enhance self-operated technology services, with significant investments in AI [11][12] Group 3 - The report indicates that the secondary market is under pressure, with new infrastructure turnover rates leading the market, as evidenced by the issuance of 14 public REITs in 2025, a decrease from the previous year [13][14] - The REITs index has faced declines, with the market's total value dropping to 215.894 billion yuan, while the trading activity has increased slightly [14][15] - New infrastructure sectors are showing higher turnover rates, particularly in park infrastructure, which is leading in transaction volume [15] Group 4 - The report notes that competition in the food delivery sector is intensifying, leading to significant pressure on profits, with the company reporting a revenue of 91.8 billion yuan in Q2 2025, a year-on-year increase of 12% [18][19] - The core local business revenue grew by 8% to 65.3 billion yuan, but operating profits fell sharply due to increased delivery subsidies and marketing expenses [19][20] - The company is optimistic about its long-term growth potential in instant delivery and overseas expansion despite short-term profit pressures [21][22] Group 5 - The report highlights the company's investments in digital and cultural sectors, with a stable revenue of 1.179 billion yuan in H1 2025, and a focus on expanding its digital technology and cultural offerings [23][24] - The online gaming segment showed a revenue increase of 9% to 706 million yuan, while the digital marketing services revenue grew by 14% [24][25] - The company is actively investing in various innovative business areas, including digital sports and arts, to enhance its market presence [25][26] Group 6 - The report indicates that the company achieved a revenue of 13.38 billion yuan in H1 2025, a year-on-year increase of 27.9%, with a significant rise in overseas sales [31][32] - The company is focusing on expanding its IP matrix and targeting a broader age demographic, with a notable increase in sales from online channels [33][34] - The company is adjusting its revenue forecasts for 2025-2027, expecting revenues of 34.18 billion yuan, 47.16 billion yuan, and 57.25 billion yuan respectively [36]

Core Insights - The report maintains a positive outlook on the agricultural sector, particularly in the pig farming industry, with a focus on the potential for value reassessment of pig farming companies [2][5] - The agricultural sector has shown a mixed performance recently, with the overall index up by 2.02% week-on-week, while the pig farming segment has seen a notable increase of 4.39% [11][12] Livestock Farming Data Tracking - Pig prices have slightly declined this week due to sufficient supply and market sentiment being buoyed by government stockpiling efforts [7][16] - The number of breeding sows has shown a slight decrease, with July figures indicating a 0.02% month-on-month decline [20][22] - The average price for market pigs as of August 28 is 13.70 CNY/kg, reflecting a week-on-week decrease of 1.51% [30][36] - Profitability in pig farming remains positive for self-bred pigs, with a profit of 32.24 CNY per head, while purchased piglets show a loss of 148.41 CNY per head [38][41] Poultry Farming Data Tracking - The price of white feathered chickens remains stable, with an average price of 7.33 CNY/kg as of August 29 [39][42] - The ongoing avian influenza outbreaks in Europe and the U.S. create uncertainty in the supply of breeding chickens, which may benefit the white feathered chicken industry [39][40] Animal Health Data Tracking - The demand for animal health products is expected to rebound, driven by the recovery in livestock numbers and the introduction of new products [47] - Significant growth in the issuance of veterinary vaccine approvals has been noted, particularly for African swine fever vaccines, which may enhance market interest [47][51] Seed Industry Data Tracking - The average prices for wheat, soybean meal, and corn have decreased slightly, with wheat at 2429 CNY/ton, soybean meal at 3071 CNY/ton, and corn at 2365 CNY/ton as of August 29 [52][53] - The USDA's August report indicates a decrease in global corn stocks for the 2025/26 season compared to the previous year, while soybean stocks are also projected to decline [54][56] Pet Industry Data Tracking - Pet food exports have seen a decline, with July figures showing a 3.0% year-on-year decrease, amounting to 930 million CNY [58][60] - Domestic sales in the pet food market continue to grow, with notable increases in sales for brands like Guai Bao and Pei Di [60][61] - The recent Asia Pet Expo showcased over 2600 exhibitors and more than 20000 brands, indicating a robust growth in the pet industry [61][62]

Core Viewpoint - The company has demonstrated strong revenue growth and improved profitability in the first half of 2025, driven by its core business in veterinary biological products and successful new product developments [1][2][3]. Financial Performance - In H1 2025, the company achieved operating revenue of 487 million yuan, a year-on-year increase of 21.67% - The net profit attributable to the parent company was 220 million yuan, up 44.09% year-on-year - The net profit after deducting non-recurring gains and losses was 190 million yuan, reflecting a 43.12% increase year-on-year - In Q2 2025, the operating revenue reached 242 million yuan, a year-on-year growth of 23.79% - The net profit attributable to the parent company for Q2 was 112 million yuan, marking a 70.78% increase year-on-year [1]. Business Segments - The veterinary biological products segment generated revenue of 461 million yuan in H1 2025, representing a year-on-year growth of 28.35% - The gross profit margin improved to 67.28%, an increase of 4.04 percentage points year-on-year - The net profit margin reached 45.00%, up 6.99 percentage points year-on-year - The company effectively controlled its operating expenses, with the sales expense ratio decreasing by 3.48 percentage points and the management expense ratio down by 0.34 percentage points [2]. R&D and Innovation - The company has made significant progress in new product development, obtaining new veterinary drug certificates for several vaccines, including: - A new live vaccine for bovine mycoplasma (HB150 strain) - A combined live vaccine for swine fever and rabies - A trivalent inactivated vaccine for swine infectious gastroenteritis, porcine epidemic diarrhea, and porcine deltacoronavirus - A four-component inactivated vaccine for avian diseases [3]. Strategic Initiatives - The company is expanding into the feed protein and pig farming sectors, aligning with national strategies for reducing feed protein usage - Collaborations with key laboratories are underway to explore the use of black soldier fly and microorganisms for converting agricultural waste into insect protein - The subsidiary, Zhule Tianyuan, achieved operating revenue of 20.78 million yuan in H1 2025 [4]. Profit Forecast and Investment Rating - Based on the company's ongoing positive performance, revenue forecasts for 2025-2027 have been adjusted to 1.13 billion, 1.35 billion, and 1.56 billion yuan, reflecting year-on-year growth rates of 20.01%, 19.65%, and 15.26% respectively - The net profit forecasts for the same period are 475 million, 566 million, and 646 million yuan, with year-on-year growth rates of 24.12%, 19.20%, and 14.17% - The current price-to-earnings ratios are projected to be 18x, 15x, and 13x respectively, maintaining a "buy" rating due to the rich new product pipeline [4].